These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36217496)

  • 1. Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer.
    Kosaka Y; Saeki T; Takano T; Aruga T; Yamashita T; Masuda N; Koibuchi Y; Osaki A; Watanabe J; Suzuki R
    Int J Nanomedicine; 2022; 17():4567-4578. PubMed ID: 36217496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
    Fujiwara Y; Mukai H; Saeki T; Ro J; Lin YC; Nagai SE; Lee KS; Watanabe J; Ohtani S; Kim SB; Kuroi K; Tsugawa K; Tokuda Y; Iwata H; Park YH; Yang Y; Nambu Y
    Br J Cancer; 2019 Mar; 120(5):475-480. PubMed ID: 30745582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer.
    Kato K; Chin K; Yoshikawa T; Yamaguchi K; Tsuji Y; Esaki T; Sakai K; Kimura M; Hamaguchi T; Shimada Y; Matsumura Y; Ikeda R
    Invest New Drugs; 2012 Aug; 30(4):1621-7. PubMed ID: 21728023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel.
    Hamaguchi T; Matsumura Y; Suzuki M; Shimizu K; Goda R; Nakamura I; Nakatomi I; Yokoyama M; Kataoka K; Kakizoe T
    Br J Cancer; 2005 Apr; 92(7):1240-6. PubMed ID: 15785749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation.
    Nakamura I; Ichimura E; Goda R; Hayashi H; Mashiba H; Nagai D; Yokoyama H; Onda T; Masuda A
    Int J Nanomedicine; 2017; 12():1293-1304. PubMed ID: 28243090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel.
    Negishi T; Koizumi F; Uchino H; Kuroda J; Kawaguchi T; Naito S; Matsumura Y
    Br J Cancer; 2006 Sep; 95(5):601-6. PubMed ID: 16909136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation.
    Hamaguchi T; Kato K; Yasui H; Morizane C; Ikeda M; Ueno H; Muro K; Yamada Y; Okusaka T; Shirao K; Shimada Y; Nakahama H; Matsumura Y
    Br J Cancer; 2007 Jul; 97(2):170-6. PubMed ID: 17595665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors.
    Mukai H; Kato K; Esaki T; Ohsumi S; Hozomi Y; Matsubara N; Hamaguchi T; Matsumura Y; Goda R; Hirai T; Nambu Y
    Invest New Drugs; 2016 Dec; 34(6):750-759. PubMed ID: 27595901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.
    Emoto S; Yamaguchi H; Kishikawa J; Yamashita H; Ishigami H; Kitayama J
    Cancer Sci; 2012 Jul; 103(7):1304-10. PubMed ID: 22429777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis.
    Taheri A; Rad A; Sadeghi E; Varshosaz J
    Curr Pharm Des; 2021; 27(17):2041-2055. PubMed ID: 32940171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
    Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
    Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial.
    Shi M; Gu A; Tu H; Huang C; Wang H; Yu Z; Wang X; Cao L; Shu Y; Wang H; Yang R; Li X; Chang J; Hu Y; Shen P; Hu Y; Guo Z; Tao M; Zhang Y; Liu X; Sun Q; Zhang X; Jiang Z; Zhao J; Chen F; Yu H; Zhang W; Sun J; Li D; Zhou J; Han B; Wu YL
    Ann Oncol; 2021 Jan; 32(1):85-96. PubMed ID: 33130217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer.
    Park IH; Sohn JH; Kim SB; Lee KS; Chung JS; Lee SH; Kim TY; Jung KH; Cho EK; Kim YS; Song HS; Seo JH; Ryoo HM; Lee SA; Yoon SY; Kim CS; Kim YT; Kim SY; Jin MR; Ro J
    Cancer Res Treat; 2017 Jul; 49(3):569-577. PubMed ID: 27618821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer.
    Anzai M; Morikawa M; Okuno T; Umeda Y; Demura Y; Sonoda T; Yamaguchi M; Kanno K; Shiozaki K; Ameshima S; Akai M; Ishizuka T
    Medicine (Baltimore); 2017 Dec; 96(51):e9320. PubMed ID: 29390506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
    Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
    JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
    Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
    Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.